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(Arg)9-SH2 superbinder: a novel promising
anticancer therapy to melanoma by
blocking phosphotyrosine signaling
An-dong Liu1†, Hui Xu1,2†, Ya-nan Gao1, Dan-ni Luo1, Zhao-feng Li1, Courtney Voss3, Shawn S. C. Li3
and Xuan Cao1,4,5,6*

Abstract
Background: Melanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted
therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is
inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows potent antitumor ability
by replacing natural SH2-containing proteins and blocking multiple pY-based signaling pathways. Polyarginine
(Arg)9, a powerful vector for intracellular delivery of large molecules, could transport therapeutic agents across
cell membrane. The purpose of this study is to construct (Arg)9-SH2 superbinder and investigate its effects on
melanoma cells, expecting to provide potential new approaches for anti-cancer therapy and overcoming the
unavoidable drug resistance of single-targeted antitumor agents.
Methods: (Arg)9 and SH2 superbinder were fused to form (Arg)9-SH2 superbinder via genetic engineering. Pull
down assay was performed to identify that (Arg)9-SH2 superbinder could capture a wide variety of pY proteins.
Immunofluorescence was used to detect the efficiency of (Arg)9-SH2 superbinder entering cells. The proliferation
ability was assessed by MTT and colony formation assay. In addition, wound healing and transwell assay were
performed to evaluate migration of B16F10, A375 and A375/DDP cells. Moreover, apoptosis caused by (Arg)9-SH2
superbinder was analyzed by flow cytometry-based Annexin V/PI. Furthermore, western blot revealed that (Arg)9SH2 superbinder influenced some pY-related signaling pathways. Finally, B16F10 xenograft model was established
to confirm whether (Arg)9-SH2 superbinder could restrain the growth of tumor.
Results: Our data showed that (Arg)9-SH2 superbinder had the ability to enter melanoma cells effectively and
displayed strong affinities for various pY proteins. Furthermore, (Arg)9-SH2 superbinder could repress proliferation,
migration and induce apoptosis of melanoma cells by regulating PI3K/AKT, MAPK/ERK and JAK/STAT signaling
pathways. Importantly, (Arg)9-SH2 superbinder could significantly inhibit the growth of tumor in mice.
Conclusions: (Arg)9-SH2 superbinder exhibited high affinities for pY proteins, which showed effective anticancer
ability by replacing SH2-containing proteins and blocking diverse pY-based pathways. The remarkable ability of
(Arg)9-SH2 superbinder to inhibit cancer cell proliferation and tumor growth might open the door to explore the
SH2 superbinder as a therapeutic agent for cancer treatment.
Keywords: Melanoma, Phosphorylated tyrosine proteins, SH2 superbinder, Cell penetrating peptides, Drug
resistance
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Background
Melanoma, which can be cured by surgery in the early
stage but the prognosis is poor, accounts for about 80%
of skin cancer deaths. This is largely because metastatic
malignancy is refractory to conventional therapies [1–4].
Gene mutations, mostly BRAF mutations, are present in
over half of all human melanomas. Although patients
with BRAF-mutant are highly sensitive to small molecule inhibitors, like Vemurafenib and Dabrafenib, most
patients display partial responses to clinical treatment,
which can eventually worsen conditions or cause death
due to drug resistance within 6 to 12 months [5–7].
Moreover, patients that lack gene mutations have few
effective therapeutic methods. These patients are associated with unique risk factors, pathophysiologic, clinical,
and prognostic features that differ from those related to
BRAF tumors [8]. Thus, it is necessary and urgent to
address the problems of drug resistance to inhibitors
with BRAF-mutant and lacking appropriate therapies for
patients without specific mutations.
Src Homology 2 (SH2) domains specifically recognize
phosphorylated tyrosine and mediate cell signal transduction [9, 10]. The “superbinder” SH2 domain, with
triple-point mutants Thr8Val/Cys10Ala/Lys15Leu, abbreviated SH2 superbinder, which could bind pY-containing
peptides with much stronger affinity than natural SH2
domains or traditional anti-pY antibody (4G10) [11, 12].
Conventional drugs are generally directed against a single
gene or protein and most of melanoma patients develop
drug resistance eventually [13]. SH2 superbinder, strongly
binding with diverse pY sites to block related signal
transduction pathways, can recognize other sites instead,
even if mutation alters the pY site [14, 15]. Therefore, SH2
superbinder can achieve the purpose of killing cancer cells
[16]. These advantages might resolve problems of drug
resistance due to gene mutation and lack of suitable
targeting drugs described above. However, it is urgent to
settle the problem of transporting SH2 superbinder across
cell membrane barriers.
Cell penetrating peptides (CPPs), having ability to translocate across the plasma membranes, are confined to
short sequences of less than 20 amino acids [17]. CPPs
have several advantages over conventional techniques on
cellular delivery because they are efficient for a variety of
cells, and have a potential therapeutic application [18].
Nona-arginine (Arg)9, as one kind of CPPs, has been
applied efficaciously to translocate across the cell membrane and deliver large cargo molecules such as peptides,
proteins, and oligonucleotides into cells with no severe
side effects, which has a prospect of wide application and
a development potential in drug delivery [19, 20].
(Arg)9-SH2 superbinder (referred as (Arg)9-GST SH2
TrM) was conducted by genetic engineering approach.
The results validated that (Arg)9-SH2 superbinder had
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strong ability to translocate into cells and played a role in
melanoma cells by binding with various pY proteins.
Furthermore, (Arg)9-SH2 superbinder could suppress
proliferation and migration of melanoma cells. Meanwhile,
apoptosis caused by (Arg)9-SH2 superbinder was observed. Additionally, PI3K/AKT, MAPK/ERK and JAK/
STAT pathways were also affected by (Arg)9-SH2 superbinder. Moreover, (Arg)9-SH2 superbinder could inhibit the
growth of tumor in vivo. Above all, (Arg)9-SH2 superbinder, which could translocate into cells efficaciously and
provide a novel anticancer method for melanoma via capturing multiple pY-containing proteins, might be a potent
candidate in the targeted therapy of melanoma.

Methods
Construction, expression and purification of GST fusion
proteins

Genes encoding the human wild type and triple-mutant
Src SH2 domains, from the pEGFP-C3-Src SH2 Wt/
TrM plasmids, were subcloned into the pGEX-4 T3 vector for expressing GST-Src SH2 Wt/TrM proteins. Based
on pGEX-4 T3-alone or pGEX-4 T3- Src-SH2 Wt/TrM,
recombinant plasmids were constructed for expressing
GST-(Arg)9, GST-Src-Wt/TrM-(Arg)9. Wt represented
Wild type. Amino acid sequences and primers of all used
constructs were listed in Additional file 1: Table S1 and
Additional file 2: Table S2 of supplementary materials.
As shown in Additional file 1: Table S1, although
nona-arginines were put at the end of C-terminus of
GST or GST-Src-SH2 Wt/TrM, we termed them as
(Arg)9-GST or (Arg)9-GST-Src-SH2 Wt/TrM.
All amplified products were gel purified using the Gel
Band Purification Kit (Beijing ComWin Biotech). The
backbone was digested with BamHI (cat. # R3136V) and
NotI (cat. # R3189V) in 37 °C for 2 h and the purified
PCR products were reacted with the linearized
pGEX-4 T3 vector at 37 °C for 30 min. The experiment
is using the One Step Cloning Kit (Vazyme, Nanjing),
according to the principle of homologous recombination. E.coli BL21 containing the expression plasmid was
grown in LB broth with 100 μg/ml ampicillin at 37 °C.
The expression of GST fusion protein was induced by
the addition of isopropyl β-D-thiogalactoside (0.5 mM
final concentration), and then incubated at 20 °C for
18 h. The lysis buffer of protein contains 20 mM
Tris-HCl (pH 7.0), 50 mM NaCl, 0.5 mM EDTA, 1 mM
dithiothreitol (DTT), 1 mM cocktail, and 1 mM PMSF.
GST fusion proteins were purified from bacterial cell lysates by glutathione-agarose beads. After sonication, cell
lysates were cleared by centrifugation at 9500 rpm for
30 min, prior to mixing with glutathione-agarose beads.
After rotating at 4 °C for 3 h, proteins could be eluted
and collected. The protein concentration in the cell
homogenates was quantified with BCA Protein Assay
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Kit. Immediately prior to their use in biological assays,
protein purity was verified by SDS-PAGE using Coomassie brilliant blue staining intensity.
Cell lines and cell culture

B16F10 melanoma cells (no metastasis variant mouse
melanoma), A375 (BRAF mutation) were purchased from
the American Type Culture Collection (ATCC, Manassas,
VA). The cisplatin (DDP)-resistant subline A375/DDP was
established with continuous exposure of the parental
A375 cells to increasing concentrations of cisplatin, ranging from 2 nM to 4 μM for about 6 months. The
drug-resistant cells were maintained in DMEM containing
4 μM cisplatin. All cells were cultured in DMEM medium
supplemented with 10% FBS and 100 U/mL penicillinstreptomycin and were maintained in a humid atmosphere
with 5% CO2 at 37 °C.
Glutathione s-transferase pull down assay and western
blot

For GST pull down assay, GST fusion proteins were
expressed in E. coli BL21 (DE3). Cells were treated with
phosphatase inhibitor sodium pervanadate (0.5 mM) for
10 min at 37 °C before harvesting. Then, cells were lysed
in ice-cold lysis buffer (0.5% NP-40, 50 mM Hepes
(pH 7.4), 1 mM magnesium chloride, 150 mM KCl, and
the complete protease inhibitor cocktail). For immunoprecipitation and western blot (immunoblot), cells were lysed
on ice in lysis buffer (1% NP-40, 50 Mm Tris-HCl
(pH 7.4), 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10%
glycerol, and the complete protease inhibitor cocktail).
The supernatant was gathered after centrifugation at
12,000 g for 15 min. Protein A/G agarose (Thermo Fisher)
and Glutathione Sepharose beads (GE Healthcare) were
used for the immunoprecipitation and GST pull down assays, respectively. Protein concentrations were quantified
by BCA method. The proteins were separated by a 10%
SDS-polyacrylamide gel and eleco-transferred onto PVDF
membranes (Millipore), which were incubated in 5% skim
milk for 1 h at room temperature. Primary antibodies
against EGFR(CST#4267), Grb2(CST#3972), pERK1/
2(CST#4370), pSTAT3(CST#4113), pAKT(CST#4060),
AKT(CST#9272), ERK1/2(CST#4695), STAT3(CST#4904),
pY antibody (Abcam EPR16871), GAPDH(CST#5174),
Bax(ABclonal#A12009) and Bcl2(ABclonal#A11025) were
diluted at 1:1000 and then incubated with the membranes
overnight at 4 °C. Membranes were washed three times
for 10 min and incubated with a 1:5000 dilution of
HRP-conjugated anti-mouse or anti-rabbit antibodies. Blots
were washed with TBST three times and developed with
the ECL system; the membranes were exposed to
ChemiDoc MP Imager (BIO-RAD). The band densities
were normalized relative to the relevant GAPDH with
Image J software.
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Immunofluorescence

1 × 104 cells were seeded in a 12-well plate and cultured
for 24 h. Cells were incubated with proteins with different time and concentrations. After washing with cold
washing buffer, cells were then fixed in 4% formaldehyde
at room temperature for 1 h, and then were permeabilized with 0.5% Triton X-100 for 20 min. After rinsing
in PBS, cells were treated with rhodamine phalloidin for
30 min and then incubated with DAPI for 5 min at RT.
Samples were imaged by a fluorescence microscope
(Olympus, Japan). The images were analyzed by Image J
software.
MTT assay

Cells collected in the logarithmic phase were plated into
96-well plates (3–5 × 103 cells/well). On the following
day, add GST fusion proteins into the cell culture
medium. After incubating for different time, 10 μL of
5 g/L MTT solutions (Sigma) were added into each well
and incubated for 4 h, and then incubated with 100 μL
DMSO for another 15 min. The optical absorbance was
measured at the wavelength of 570 nm. Different treatment time and concentrations have been shown in the
figure legends.
CCK-8 assay

Cells collected in the logarithmic phase were plated into
96-well plates (5 × 103 cells/well). On the following day,
add GST fusion proteins into cell culture medium with
different concentrations. After incubating for various
time, 10 μl CCK-8 solution (Dojindo) was added into
each well and incubated for 1-4 h. The optical absorbance was measured at the wavelength of 450 nm.
Colony formation assay

Cells were trypsinized and plated in 6-well plates (100
cells/well), incubated with GST fusion proteins and
counted 14 days after seeding. The colonies were subsequently fixed with 4% formaldehyde and stained with
0.01% crystal violet for 10 min.
Wound healing assay

Cells were seeded into six-well plates (5 × 105 cells/well).
Wounds were then created using the 200 μL pipette tips.
The scratched cells were removed by PBS for three
times. Cells were then cultured for 16 h incubated in the
presence or absence of (Arg)9-GST SH2 TrM. Microscopic
images were taken with a digital camera at different
time points.
Transwell assay

2 × 104 cells were plated in 200 μL DMEM containing 2%
FBS in the upper chamber. The lower chamber was filled
with 500 μL completed medium containing 10%FBS.
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(Arg)9-GST SH2 TrM or (Arg)9-GST were added to the
upper chamber and cells were allowed to migrate for 16 h
at 37 °C with 5% CO2. Cells were fixed with 4% formaldehyde for 15 min at room temperature. Then, cells on the
upper chamber were moved with a cotton swab. After
washing the chambers with ddH2O, cells remained on the
bottom of the lower chamber were stained with 0.1% crystal violet. The migrated clones were photographed under
a microscope. The cell numbers were counted at three
different areas.
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Preparation of PBMCs

Peripheral blood obtained from healthy C57Bl/6 mice was
anticoagulated with heparin. PBMC were isolated by Ficoll
(Germany) density gradient centrifugation of peripheral
venous blood. Cells were washed three times and resuspended in DMEM medium supplemented with 1 mM sodium pyruvate, 1% nonessential amino acids and vitamins,
2 mM L-glutamine, 100 U/ml penicillin-streptomycin and
10% FBS.
Statistical analysis

Apoptosis analysis

Cells were sedimented by centrifugation, resuspended and
fixed in 100 μl binding buffer. Cell density in the cell suspension was adjusted to 2 × 103cells/μl. Subsequently, 5 μl
Annexin V-FITC was added to the cell suspension
followed by gently vortexing and incubation for 10 min at
room temperature in the dark. Thereafter, the cell suspension was incubated with 5 μl Propidiumiodide. All details
need to refer to the instructions of kit (Tianjin Sungene
Biotech). Cells were analyzed immediately using a FACS
flow cytometer (FACS BD Biosciences, Germany) for
Annexin V-FITC and Propidiumiodide binding. Dot plots
and histograms were analyzed by Flowjo software.
TdT-UTP nick end labeling (TUNEL) assays were performed with one-step TUNEL apoptosis assay kit produced by Beyotime Institute of Biotechnology according
to the manufacturer’s instructions. The FITC-labeled
TUNEL-positive cells were imaged under a fluorescent
microscope (Olympus, Japan). The cells with green
fluorescence were defined as apoptotic cells. And images
were analyzed by Image J software.
Animal studies

Xenograft model was established on C57Bl/6 mice (Animal Center of Tongji Medical College, Wuhan), 4–6 weeks
old, weighing approximately 18-22 g. All studies involving
animals were performed following the National Guides for
the Care and Use of Laboratory Animals and approved by
the Institutional Animal Care and Use Committee of
Tongji Medical College, Huazhong University of Science
and Technology.
A suspension of 1 × 106 B16F10 cells (in 100 μl PBS)
was subcutaneously injected into the right flank each
mouse. After the development of an easily palpable
tumor (7–10 days, approximately 5 mm in diameter).
Tumor size was measured by using a caliper every 3 days
and was calculated by using the following formula:
tumor volume = 1/2(width)2 × length. Mice were divided
into control group (B16F10 cells and PBS injected) and
the experimental group (B16F10 cells and (Arg)9-GST
SH2 TrM treated), n = 3 per group. Animals were euthanized when tumor size reached the ethical end point.

The Student’s test was used to test for statistical significance
of the differences between the different group parameters.
P values of less than 0.05 were considered statistically
significant.

Results
Construction, expression and purification of GST fusion
proteins

(Arg)9, (Arg)9-SH2 Wt/TrM, and SH2 Wt/TrM-alone
(without nona-Arg) were subcloned into the pGEX-4 T3
backbone, respectively. The PCR product of SH2 Wt/TrM
was 327 bp and the pGEX-4 T3-(Arg)9-SH2 Wt/TrM was
5295 bp. DNA gel electrophoresis and sequencing were
utilized to confirm the successful construction of
pGEX-4 T3-(Arg)9-SH2 Wt/TrM (Additional file 3: Figure
S1a). Coomassie staining image showed that (Arg)9-GST
SH2 Wt/TrM and (Arg)9-GST were expressed and
glutathione-agarose beads were used to purify the
expressed proteins (Additional file 3: Figure S1b). The
molecular weight of (Arg)9-GST, (Arg)9-GST SH2 Wt/
TrM, and GST SH2 Wt/TrM are about 26 kDa, 36 kDa,
and 35 kDa, respectively.
(Arg)9-GST SH2 TrM could effectively bind with pY
proteins

To test whether (Arg)9-GST SH2 TrM could effectively bind
with pY-containing proteins, the mouse melanoma B16F10
cells were subjected to serum-free medium for 16 h, and
with or without the stimulation of EGF (100 ng/ml), and
then treated with sodium pervanadate prior to collection.
The whole cell lysates were incubated with (Arg)9-GST,
(Arg)9-GST SH2 Wt or (Arg)9-GST SH2 TrM (0.2 mg protein each reaction) for 12 h at 4 °C, and the pY-containing
proteins were enriched and pulled down by an appropriate
amount of glutathione agarose. The results showed that
almost no protein bands were seen in (Arg)9-GST control,
while pY-containing proteins from (Arg)9-GST SH2 TrM
group were more obvious than those from (Arg)9-GST SH2
Wt, and EGF can promote the phosphorylation level of
protein tyrosine residues (Fig. 1). Levels of pY proteins in
human melanoma cell A375 and its cisplatin (DDP)resistant subline A375/DDP cells were shown in Additional
file 4: Figure S2.
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fluorescence signal of (Arg)9-GST-SH2 TrM was observed.
In contrast, (Arg)9-GST in the cytoplasm couldn’t bind with
pY-containing protein complexes for the lacking of SH2
TrM domain, and the binding of (Arg)9-GST SH2 Wt to
pY-containing protein complexes was moderate, thus their
green fluorescence signal tended to be weak in the cells.

(Arg)9-GST SH2 TrM attenuated proliferation of melanoma
cells

Fig. 1 (Arg)9-GST SH2 TrM can effectively bind with pY proteins in
B16F10 cells. The whole cell lysates of B16F10 cells with or without
EGF treatment were incubated with (Arg)9-GST, (Arg)9-GST SH2 Wt
or (Arg)9-GST SH2 TrM for 12 h at 4 °C. The pY-containing proteins
were enriched, pulled down and then examined by western blot
using anti-pY antibody. Data shown are representative of three
independent experiments

As SH2 domain can specifically recognize and bind to
pY residues, SH2-containing proteins play a vital role in
the pY-based signaling transduction [21]. (Arg)9-GST
SH2 TrM exhibits strong binding ability with pY proteins in cells, therefore, it may competitively displace the
natural SH2-containing proteins and block a number of
pY-based signaling pathways in cells.
(Arg)9-GST SH2 TrM could efficiently penetrate into
melanoma cells

To identify the transmembrane ability of (Arg)9-GST SH2
TrM, B16F10 cells were incubated with proteins at different concentrations (0.5, 0.75,1 and 2 μM) for 2 h. The
results showed that (Arg)9-GST SH2 TrM could enter
cells efficiently, and 1 μM was an optimal concentration
(Fig. 2a). Cells were incubated with 1 μM protein at
different time (0.5 h,1 h,2 h and 4 h), and 2 h was found
to be the appropriate time (Fig. 2b). As shown in Fig. 2c,
(Arg)9-fused proteins could translocate into cells, whereas
those without nona-arginine failed to do so (left panel).
Furthermore, the green fluorescence signal of (Arg)9-GST
or (Arg)9-GST SH2 Wt was observed to be weaker than
that of (Arg)9-GST-SH2 TrM (right panel). (Arg)9-GST-SH2
TrM protein could be enriched in the cells via tightly binding with pY-containing protein complexes, so strong green

To investigate the ability of (Arg)9-GST SH2 TrM to
inhibit the proliferation of B16F10 cells, MTT assay was
conducted. After the fusion proteins, including GST,
GST SH2 Wt, GST SH2 TrM, (Arg)9-GST, (Arg)9-GST
SH2 Wt and (Arg)9-GST SH2 TrM, were used at varying
concentrations of 0.5, 1, 2, 4 and 8 μM, or different
treatment time of 1,2,4 and 8 h, 1 μM for 2 h was the
optimal choice to attenuate the proliferation of B16F10
cells (Fig. 3a and b). The results were verified to be similar for A375 cells (Additional file 5: Figure S3) and
A375/DDP cells (Additional file 6: Figure S4). To further
confirm the reduction in cellular viability, colony formation assay was performed. Compared with the control
group, the clonogenic ability of melanoma cells was
drastically decreased after incubated with 1 μM
(Arg)9-GST SH2 TrM (Fig. 4a). These data provided evidence that (Arg)9-GST SH2 TrM restrained proliferation
of melanoma cells in vitro.
Targeting tyrosine kinases that can drive tumorigenesis is an effective strategy in molecular targeted therapy [22, 23]. EGFR family members are associated with
many epithelial cancers [24, 25]. Due to its strong binding ability with pY-containing proteins, (Arg)9-GST
SH2 TrM may decrease the tyrosine phosphorylation
level of proteins derived from EGFR and act as an
inhibitor of EGFR signaling and EGF-dependent cell
growth. Moreover, Grb2, a critical adaptor protein in
EGFR signaling [26], was found to bind less to EGFR
after cells treated with (Arg)9-GST SH2 TrM (Fig. 4b).
This indicated that (Arg)9-GST SH2 TrM effectively
inhibited the EGF-dependent pathways, likely by competing for binding to the pY sites on the EGFR. Both MAPK/
ERK and PI3K/AKT pathways are critical downstream
pathways in the proliferation of cancer cells [27–29].
(Arg)9-GST SH2 TrM drastically reduced the phosphorylation of ERK and AKT(Fig. 4c), which are the downstream
kinases of the EGFR signaling pathways [30]. The results
of A375 and A375/DDP cells were similar to B16F10 cells,
and (Arg)9-GST SH2 TrM reduced the phosphorylation
of ERK and AKT (Additional file 7: Figure S5a). These
results proved that (Arg)9-GST SH2 TrM blocked the
EGFR signal pathway and the downstream PI3K/AKT and
MAPK/ERK signaling pathways in the proliferation of
melanoma cells.
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Fig. 2 (Arg)9-GST SH2 TrM could efficiently enter into B16F10 cells. Effects of (Arg)9-GST SH2 TrM translocating into B16F10 cells at different
concentrations (0.5, 0.75,1 and 2 μM) (a) and various time (0.5 h,1 h,2 h and 4 h) (b). c Distinct penetration ability of GST, GST SH2 Wt, GST SH2
TrM, (Arg)9-GST, (Arg)9-GST SH2 Wt and (Arg)9-GST SH2 TrM proteins. Cells were stained with anti-GST antibody followed by goat-anti-rabbit FITC
secondary antibody. Actin was stained with Rhodamine-phallodin (Red) and nucleus with DAPI (Blue). Scale bar: 20 μm. All images shown are
representative of at least three independent experiments

(Arg)9-GST SH2 TrM inhibited the migration of melanoma
cells

To examine whether (Arg)9-GST SH2 TrM may inhibit the
migration of melanoma cells, the effect of (Arg)9-GST SH2
TrM on migration of cells was monitored by wound
healing assay. Cells were seeded in six-well plates, and
cultured with complete cell medium or contained with
1 μM (Arg)9-GST or (Arg)9-GST SH2 TrM after stimulated
with EGF (100 ng/ml). Melanoma cells treated with
(Arg)9-GST SH2 TrM had limited ability of migration after
scratched for 16 h (Fig. 5a). Furthermore, Transwell system
was used to assess the ability of migration. Cell numbers of
the group that treated with (Arg)9-GST SH2 TrM for 16 h
were drastically less than those of the control group (Fig.
5b). These data indicated that the migration of melanoma
cells was inhibited by (Arg)9-GST SH2 TrM.
(Arg)9-GST SH2 TrM induced apoptosis of B16F10 cells

In the previous trials, the phenomenon of cell death after
treated with (Arg)9-GST SH2 TrM appeared, and the
number of dead cells increased over time. To investigate
whether the cell death was induced by apoptosis, B16F10
cells were treated with (Arg)9-GST SH2 TrM at 1 μM for

different time intervals (1 h,2 h and 3 h). The apoptotic
cell fractions of B16F10 cells that received different treatment time are shown in Fig. 6a. The results showed that
the number of apoptotic cells (Q2 + Q3, Q2 and Q3 represented cells at phases of late and early of apoptosis,
respectively) both significantly increased as the time of
incubation increasing from 0 h to 3 h. And number of
necrotic cells(Q1) increased over time. As revealed by flow
cytometry analysis, the percentage of apoptosis cells
reached 42.56, 56 and 62.4% for 1 h, 2 h or 3 h group
respectively, which is 10-fold higher than the 0 h group
(Fig. 6a). These results suggested that (Arg)9-GST SH2
TrM facilitated cell apoptosis, which was the main cause of
in vitro cell death after (Arg)9-GST SH2 TrM incubation.
It is known that Bax and Bcl2 play a pivotal role in the
regulation process of apoptosis [31, 32]. The results
showed that Bax was increased and Bcl-2 was decreased
after treating with (Arg)9-GST SH2 TrM, enhancing that
(Arg)9-GST SH2 TrM could promote apoptosis in B16F10
cells (Fig. 6b). JAK/STAT signaling pathway is involved in
cell cycle progression and apoptosis [33, 34]. STAT3 was
detected to understand the mechanism of apoptosis
caused by (Arg)9-GST SH2 TrM. The pSTAT3 level was
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Fig. 3 Effects of GST, GST SH2 Wt, GST SH2 TrM, (Arg)9-GST, (Arg)9-GST SH2 Wt and (Arg)9-GST SH2 TrM on the proliferation of B16F10 cells. Cells were
treated with different GST-fused proteins or PBS (as control) at different concentrations (a) (0.5, 1, 2, 4 and 8 μM) for various time (b) (1,2,4 and 8 h) and
cell viability was measured by MTT assay (n = 3, *P < 0.05)

declined after treated with (Arg)9-GST SH2 TrM (Fig. 6c).
As shown in Additional file 7: Figure S5b, the phosphorylation of STAT3 also decreased in the A375 and A375/
DDP cells. These data revealed that (Arg)9-GST SH2 TrM
might lead to melanoma cell death progression via blocking JAK/STAT signal pathway.
(Arg)9-GST SH2 TrM suppressed the growth of B16F10
cells on tumor-bearing mice

To further confirm the role of (Arg)9-GST SH2 TrM in
vivo, mice were injected subcutaneously with 1 × 106
B16F10 cells on the right flanks. Since the 9th day, mice
were injected with (Arg)9-GST SH2 TrM or PBS through
tail vein twice a day (10 mg/kg). Tumor volumes of
(Arg)9-GST SH2 TrM group were found to be much

smaller than those of the PBS group. The results demonstrated that (Arg)9-GST SH2 TrM resulted in pronounced
regression of B16F10 tumors (Fig. 7a and b). HE staining
was utilized to observe the changes of tumor cell morphology. The images illustrated (Arg)9-GST SH2 TrM resulted in high level of necrosis lesions in tumors (Fig. 7c).
The sections of tumors were assayed for apoptosis analysis
using a TUNEL kit that labels apoptotic nuclei with a
green fluorescent marker. The incidence of apoptosis in
(Arg)9-GST SH2 TrM-treated group was significantly
higher than PBS group (Fig. 7d). These data demonstrated
that (Arg)9-GST SH2 TrM could be an effective therapy
to melanoma and induce apoptosis of B16F10 melanoma in vivo. The ability of (Arg)9-SH2 superbinder to
reduce the tumor burden in xenograft mice suggested
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Fig. 4 Proliferation capacity of melanoma cells was suppressed by (Arg)9-GST SH2 TrM. a Representative images of colony formation assay
showing colonies formed by B16F10 cells incubated with (Arg)9-GST SH2 TrM or (Arg)9-GST (n = 3, *P < 0.05). b (Arg)9-GST SH2 TrM treatment
blocked the EGFR-Grb2 signaling of B16F10 cells. IP, immunoprecipitation; IB, immunoblot. WCL, whole cell lysates. c (Arg)9-GST SH2 TrM
treatment reduced the phosphorylation of ERK and AKT of B16F10 cells. Data shown are representative of three independent experiments

that (Arg)9-SH2 superbinder represented a novel strategy for the treatment of melanoma.
Undoubtedly, (Arg)9-GST-SH2 TrM protein must subject to the proteolysis in the bloodstream. To investigate
its stability in blood, (Arg)9-GST-SH2 TrM protein was
added into the dish with normal mouse serum (Abbkine,
China) and the dish was gently shaken under 37 °C to
mimic the condition of bloodstream. As shown in Fig. 7e,
degradation of (Arg)9-GST SH2 TrM in the serum was
checked by Western Blot with anti-GST antibody, and the
fusion protein almost degraded at the time point of 4 h.
At the same time, the stability of (Arg)9-GST-SH2 TrM
protein in the lysated tumor tissue from B16F10 Xenograft
mice was checked. The total level of GST-fused protein
gradually increased from 1 h to 4 h, but (Arg)9-GST-SH2
TrM protein was observed to obviously degrade at the
time point of 4 h (Fig. 7f). Furthermore, the phosphorylation level of tyrosine proteins in the lysated tumor tissue
was examined by Western Blot with anti-pY antibody. The
phosphorylation level of tyrosine proteins in the lysated

tumor tissue from B16F10 Xenograft mice drastically decreased at 4 h after the injection of (Arg)9-GST-SH2 TrM
(Fig. 7g), which indicated that (Arg)9-GST-SH2 TrM protein significantly blocked the pY-based signaling pathways
by the strong binding with pY proteins in the tumor cells.
All above data demonstrated that (Arg)9-GST-SH2 TrM
protein exhibited excellent anti-tumor functions in spite
of the proteolysis in vivo.

Discussion
Patients, with BRAF (V600) in 40–60% of melanomas, can
be successfully cured with selective inhibitors, bringing
about significant prolongation of progression free survival
and overall survival [35, 36]. Although BRAF inhibitors
are effective treatment methods, drug resistance is inevitable, and high drug prices increase the burden on patients
[37–39]. Meanwhile, the remaining 50–60% of patients
are BRAF wild type and they do not benefit from treatment with BRAF inhibitors. A number of other mutations
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Fig. 5 (Arg)9-GST SH2 TrM repressed migration of melanoma cells. a Wound healing assays were monitored at 0 h and 16 h for B16F10, A375
and A375/DDP cells treated with (Arg)9-GST SH2 TrM or (Arg)9-GST. Scale bar: 100 μm. b Transwell migration assays of B16F10, A375 and A375/
DDP cells treated with (Arg)9-GST SH2 TrM or (Arg)9-GST at 1 μM for 16 h (n = 3, *P < 0.05). Scale bar: 20 μm. All images shown are representative
of at least three independent experiments

are present in these patients, such as NRAS, MEK1/2 and
atypical (non-V600) BRAF mutations [8]. Treatment of
this subset of patients without a BRAFV600 mutation is a
challenging problem.
EGF, an extracellular signal factor, can activate
downstream Ras, by binding with the EGFR, and then
phosphorylate Raf, decreasing Ras-GTPase activity. The
EGF-dependent signal pathways are closely related with
tumorigenesis [40]. BRAF, an important member of Raf

family, is the downstream effector of RAS. Protein
tyrosine phosphorylation plays an essential role in the
development and progression of cancer. Aberrant tyrosine phosphorylation is associated with cancer [41, 42];
Carcinogenic cells tend to exhibit abnormal high levels
of phosphorylated tyrosine [43, 44]. Previous studies
have proved that the inactivation of MAPK/ERK signaling pathways can regulate migration of HEK293T cells
[16]. The tight combination of SH2 superbinder and
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Fig. 6 (Arg)9-GST SH2 TrM induced apoptotic death of B16F10 cells. a Flow cytometry measurement of cell apoptosis induced by (Arg)9-GST SH2
TrM at different time of incubation (n = 3, *P < 0.05). Q1: necrotic cells, Q2: late apoptotic cells; Q3: early phase apoptotic cells; Q4: normal cells.
b (Arg)9-GST SH2 TrM treatment regulated the expression of Bax and Bcl-2. c Level of pSTAT3 and STAT3 was examined by Western Blot. GAPDH
was used as a loading control. All cells were incubated with (Arg)9-GST SH2 TrM at 1 μM for 2 h before collected. Data shown are representative
of three independent experiments

EGFR could block the activation of downstream signaling pathways [16]. Similarly, our results substantiated
that levels of pAKT, pERK1/2 and pSTAT3 were reduced
by (Arg)9-SH2 superbinder via blocking the EGFR
signaling pathway. Remarkably, the effects of (Arg)9-SH2
superbinder on pathways described above were involved
in the regulation of cell apoptosis. There are a large
number of members in Bcl-2 family involved in regulation of apoptosis, such as Bcl-2, Bcl-X1, Bcl-w, Bax, Bad,
Bak, Bcl-xs, Mc1–1 et al. Bcl-2 and Bax, two most popular members of this family, were chosen to be examined
in this study. The results indicated pro-apoptotic protein
Bax increased and anti-apoptosis protein Bcl-2 declined
in B16F10 cells after (Arg)9-SH2 superbinder incubation.
Of course, it needs further investigations to check
whether other members in Bcl-2 family mediate the
process of (Arg)9-SH2 superbinder-induced apoptosis in
future.
In addition, the powerful vector (Arg)9, for the intracellular delivery of conjugated large molecules, was applied
efficaciously to translocate across the cell membrane and

transport SH2 superbinder into the cytoplasm or nucleus
of B16F10 cells. The results showed that fluorescence
intensity of cells incubated with (Arg)9-GST SH2 TrM
was higher than that of (Arg)9-GST because of the strong
affinity between (Arg)9-GST SH2 TrM and pY-containing
proteins in cells. Indeed, cell penetrating peptides inevitably have some toxicity effect on the cells. The MTT data
in our work showed that (Arg)9-GST protein exhibited
remarkably low toxicity, which is consistent with previous
reports [45, 46]. In brief, (Arg)9 overcame the challenge of
transporting therapeutic agents across cell membrane
which showed a great value of application in biomedical
system. Furthermore, we isolated the peripheral blood
mononuclear cells(PBMCs) from mice and evaluated the
penetration and toxicity effect of (Arg)9 fused proteins on
PBMCs. As shown in Additional file 8: Figure S6a, the
level of pY was very low in PBMCs as the non-cancerous
cells. (Arg)9-GST-SH2 TrM protein could enter into
PBMCs, but the green signal was very weak (Additional
file 8: Figure S6b). Indeed, (Arg)9-GST-SH2 TrM protein
caused some toxicity effect on PBMCs according to the
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Fig. 7 (Arg)9-GST SH2 TrM resulted in apoptosis and inhibited proliferation of B16F10 cells in vivo. a Effect of (Arg)9-GST SH2 TrM on the growth
of B16F10 tumors. The changes of tumor volumes were shown between (Arg)9-GST SH2 TrM and PBS control (n = 3, *P < 0.05). b Tumors were
resected after 30 days of treatment. Tumor volumes from (Arg)9-GST SH2 TrM group were smaller than the PBS group. c HE staining of xenograft
tumors from mice injected with (Arg)9-GST SH2 TrM (left) or PBS (right). (Arg)9-GST SH2 TrM resulted in high level of necrosis lesions in tumors.
Scale bar: 50 μm. d TUNEL assay for B16F10 tumors after treated with or without (Arg)9-GST SH2 TrM. The apoptotic nuclei were stained with a
fluorescent marker (green). Scale bar: 50 μm. e Degradation of (Arg)9-GST SH2 TrM in normal mouse serum was evaluated by Western Blot with
anti-GST antibody. f and g Tumors were resected and lysated at different time points after the injection of (Arg)9-GST SH2 TrM protein. The level
of GST-fused proteins in tumor tissue was examined by Western Blot with anti-GST antibody (f). The phosphorylation level of tyrosine proteins in
tumor tissue was checked by Western Blot with anti-pY antibody. All images shown are representative of at least three independent experiments

CCK-8 data (Additional file 9: Figure S7), but it was
moderate as (Arg)9-GST-SH2 TrM protein specifically
recognizing and binding to pY residues, whereas the level
of pY residues was verified to be very low in PBMCs.
These findings suggested that (Arg)9-SH2 superbinder
could play a significant role in the progression of cell
proliferation, migration and apoptosis. Importantly,
these data implied that (Arg)9-SH2 superbinder, targeting multiple pY proteins, might be a useful anticancer

therapy to address the difficulties of resistance and provide a novel effective way for melanoma.

Conclusions
In summary, it is the first time to combine (Arg)9 with
SH2 superbinder to form a drug delivery system. The
findings indicated (Arg)9-SH2 superbinder had potent
antitumor ability by targeting various pY proteins and
blocking diverse pY-based signaling pathways. The
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results verified that (Arg)9-SH2 superbinder could suppress proliferation, migration, and induce apoptosis of
melanoma cells via regulating the activity of PI3K/AKT,
MAPK/ERK and JAK/STAT signal pathways. (Arg)9-SH2
superbinder had the potential to act as a promising
therapy for melanoma and displayed a prospective value
of application.
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